Vadivarhe Speci. (VSCL)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales grew 17.76%, showing some demand traction for the business.
• Promoter holding is high at 66.83%, aligning management with shareholders.
• Market cap is small at ₹32 crore, so a genuine operational recovery could move the needle.
• Current price is well above the 52-week low of ₹16.05, indicating some market interest.

Concerns

• Net loss of ₹4 crore on ₹17 crore quarterly sales means the company is deeply unprofitable.
• ROCE is -22.66%, reflecting poor capital efficiency and value destruction.
• Piotroski F-Score of 3/9 signals weak financial health.
• No dividend, no positive P/E, and unavailable book value offer no fundamental support.

AI Analysis

Vadivarhe Specialities is the kind of stock Benjamin Graham would call a speculation, not an investment. The market cap is only ₹32 crore and the latest quarter shows sales of ₹17 crore, but the company lost ₹4 crore in that quarter. That is a roughly 24% negative margin. The return on capital employed is -22.66%, so every rupee kept in this business is earning less than nothing. With a Piotroski F-Score of 3 out of 9, the financial health is weak. There is no dividend to wait for. The P/E is meaningless because there is no earnings power, and with book value not available, I cannot calculate any margin of safety. Sales grew 17.76%, but profit growth is -18.79%, meaning the company is doing more work while losing more money. That is not a growth story; it is a cash consumption story. Promoters hold 66.83%, which is good alignment, but high ownership cannot replace a sound business model. The 52-week range of ₹16.05 to ₹31.60 and the current price of ₹26.65 show the market is paying a speculative premium to the recent low. As value investors, we must avoid being seduced by a rising sales line. A specialty chemicals business can have a niche, but without positive return on capital and a credible path to net profit, it has no moat. I need to see margins improve, ROCE move toward positive territory, and debt levels under control. Convert the ₹17 crore quarterly sales into even a small profit, and the math becomes interesting. Until then, this is a turnaround candidate only if management proves it. I will stay on the sidelines and wait for concrete evidence.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer